Your browser is no longer supported. Please, upgrade your browser.
Settings
MNKD [NASD]
MannKind Corporation
Index- P/E- EPS (ttm)-0.33 Insider Own1.70% Shs Outstand249.91M Perf Week3.70%
Market Cap1.19B Forward P/E- EPS next Y-0.22 Insider Trans0.25% Shs Float237.13M Perf Month-7.44%
Income-79.30M PEG- EPS next Q-0.07 Inst Own43.80% Short Float10.85% Perf Quarter-4.68%
Sales81.40M P/S14.66 EPS this Y3.10% Inst Trans-1.73% Short Ratio9.46 Perf Half Y11.17%
Book/sh-0.74 P/B- EPS next Y43.30% ROA-34.50% Target Price6.25 Perf Year54.48%
Cash/sh0.52 P/C8.58 EPS next 5Y35.60% ROE43.90% 52W Range2.76 - 6.25 Perf YTD43.13%
Dividend- P/FCF- EPS past 5Y43.70% ROI82.50% 52W High-28.32% Beta1.80
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin58.60% 52W Low62.32% ATR0.23
Employees241 Current Ratio3.20 Sales Q/Q44.20% Oper. Margin-79.10% RSI (14)45.95 Volatility4.91% 5.03%
OptionableYes Debt/Eq- EPS Q/Q63.90% Profit Margin-97.40% Rel Volume1.02 Prev Close4.40
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume2.72M Price4.48
Recom1.70 SMA20-3.83% SMA50-5.19% SMA2001.03% Volume2,779,951 Change1.82%
May-14-21Initiated RBC Capital Mkts Sector Perform $5
Dec-24-19Initiated Oppenheimer Outperform $2.50
Oct-25-19Initiated Cantor Fitzgerald Overweight $3
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Dec-06-21 06:05AM  
Nov-09-21 07:55PM  
04:05PM  
06:05AM  
Nov-05-21 07:05AM  
Nov-02-21 06:05AM  
Oct-27-21 03:03PM  
Oct-20-21 01:28AM  
Oct-19-21 10:29AM  
Oct-18-21 02:38PM  
02:37PM  
12:37PM  
11:42AM  
09:20AM  
08:45AM  
06:36AM  
06:02AM  
06:00AM  
Oct-04-21 08:11AM  
07:05AM  
07:05AM  
Sep-30-21 07:43AM  
Sep-29-21 04:24PM  
Sep-28-21 10:05AM  
06:05AM  
Sep-15-21 06:05AM  
Sep-07-21 09:54AM  
06:05AM  
06:00AM  
Aug-14-21 03:40AM  
Aug-12-21 11:30AM  
Aug-11-21 05:15PM  
04:00PM  
Aug-04-21 06:48AM  
06:48AM  
06:15AM  
Aug-03-21 09:00AM  
Jul-29-21 11:00AM  
Jul-28-21 03:03PM  
Jul-09-21 04:52AM  
Jun-29-21 09:34AM  
Jun-28-21 06:15AM  
04:15AM  
Jun-25-21 11:35AM  
Jun-17-21 09:40AM  
Jun-16-21 10:59AM  
07:26AM  
06:15AM  
06:00AM  
05:04AM  
Jun-10-21 06:15AM  
Jun-08-21 05:00PM  
Jun-03-21 06:00AM  
May-25-21 04:35AM  
May-20-21 09:00AM  
May-13-21 09:00AM  
09:00AM  
08:30AM  
May-12-21 04:00PM  
May-11-21 09:00AM  
May-05-21 09:00AM  
Apr-28-21 12:33PM  
Apr-26-21 09:00AM  
Apr-19-21 06:00AM  
Mar-16-21 09:00AM  
Mar-15-21 08:00AM  
Mar-10-21 05:00PM  
Mar-02-21 05:00PM  
06:30AM  
Mar-01-21 07:00AM  
04:47AM  
Feb-26-21 10:05AM  
01:01AM  
Feb-25-21 08:00AM  
Feb-24-21 02:57PM  
08:00AM  
Feb-18-21 05:00PM  
09:00AM  
Feb-04-21 08:33PM  
Jan-04-21 05:00PM  
Dec-29-20 08:53AM  
Dec-18-20 07:45AM  
Dec-17-20 04:44PM  
Dec-10-20 08:00AM  
Dec-07-20 11:33PM  
09:20AM  
Dec-01-20 08:00AM  
Nov-30-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 05:00PM  
Nov-10-20 10:15AM  
Nov-08-20 09:37AM  
Nov-06-20 08:44PM  
Nov-04-20 05:15PM  
04:00PM  
Oct-29-20 08:00AM  
Oct-28-20 12:32PM  
Oct-23-20 10:38AM  
Sep-08-20 08:00AM  
Aug-31-20 09:00AM  
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF- inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomson DavidEVP Genl Counsel & SecretaryAug 27Sale4.644,10019,024567,391Aug 27 09:01 PM
Castagna MichaelChief Executive OfficerJul 30Buy2.995,00014,9501,538,652Aug 02 08:00 PM
Galindo AlejandroChief Commercial OfficerJul 30Buy2.995,00014,950547,602Aug 02 08:00 PM
Tross Stuart AChief People & Workpl OfficerJul 30Buy2.994,47613,383634,708Aug 02 08:00 PM
Binder Steven B.Chief Financial OfficerJul 30Buy2.997482,237547,644Aug 02 08:00 PM
Castagna MichaelChief Executive OfficerMar 05Buy3.383,00010,1403,000Mar 08 05:00 PM
Binder Steven B.Chief Financial OfficerJan 31Buy1.331,5572,071398,822Feb 02 06:18 PM
Castagna MichaelChief Executive OfficerJan 31Buy1.335,0006,6501,117,560Feb 02 06:18 PM
Tross Stuart AChief People & Workpl OfficerJan 31Buy1.335,0006,650481,991Feb 02 06:18 PM